Mon, Dec 29, 2014, 7:24 AM EST - U.S. Markets open in 2 hrs 6 mins

Recent

% | $
Quotes you view appear here for quick access.

OXiGENE, Inc. Message Board

  • vvvvvvrebel89130 vvvvvvrebel89130 Mar 26, 2014 3:42 PM Flag

    no mention of o/s from transcript

    In terms of next steps, of course we will look forward to a presentation of the full dataset at a scientific meeting later this year, which we expect to include the current (indiscernible) specific details on progression-free survival and objective response rate. In the meantime, we intend to evaluate the necessary next development and regulatory steps for the combination of ZYBRESTAT plus Avastin.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • They probably do not have enough events yet to calculate O/S. From disease progression to death could take at least several months. So I would not expect O/S data until later in the year. The longer we wait might mean good results though not guaranteed. In any case, I would expect talks with EU regulators to be mainly based on the great progression free survival number we just received since other companies have been approved on such data.
      If a large pharma wants to get a bargain price for an acquisition or partnership, they will make a move before O/S data is announced.

 
OXGN
1.63+0.04(+2.52%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
Portugal Telecom, SGPS S.A.
NYSEFri, Dec 26, 2014 4:02 PM EST